neoag
Neoantigen × AI
Daily research signal
FIELD MAP / TUMOR TYPE

Lung cancer (NSCLC)

Non-small-cell lung cancer — a high-incidence, often high-TMB setting for neoantigen vaccines combined with checkpoint blockade.

Topic17 items2026-05-30 – 2026-07-06
Tumor types
Glioblastoma25Melanoma23Pancreatic cancer19Colorectal cancer18Lung cancer (NSCLC)17Breast cancer11Liver cancer (HCC)8Kidney cancer (RCC)7Lynch syndrome7Head & neck cancer5Ovarian cancer2Gastric cancer2Prostate cancer2Bladder cancer1
01
Clinical

Safety, Tolerability, Immunogenicity, Pharmacodynamic Characteristics, and Preliminary Anti-tumor Activity of Personalized Cancer Vaccines Alone and in Combination With Toripalimab in Participants With Resected NSCLC

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School has registered a Phase 1 study evaluating personalized cancer vaccines alone and in combination with toripalimab for patients with resected non-small cell lung cancer (NSCLC). The trial features dose escalation and expansion phases to assess safety, tolerability, immunogenicity, and preliminary anti-tumor activity. This represents an early-stage clinical test of combining neoantigen-specific vaccination with checkpoint inhibition in a post-surgical setting.

clinicaltrials · brief 2026-07-06 · published 2026-07-06
02
Commercial

Transgene SA (TRGNF) Discusses Progress in Individualized Neoantigen Therapeutic Vaccines and Expansion into Early-Stage NSCLC - Slideshow (OTCMKTS:TRGNF) 2026-07-01 - Seeking Alpha

Transgene SA is expanding its pipeline of individualized neoantigen therapeutic vaccines into early-stage non-small cell lung cancer (NSCLC). The company’s recent updates highlight progress in developing personalized immunotherapies beyond their current indications, signaling an effort to diversify the application of their neoantigen platform across major oncology markets.

Transgene
news · brief 2026-07-01 · published 2026-07-01
04
Commercial

Transgene Expands myvac® into Non-Small Cell Lung Cancer with TG4070, an Individualized Neoantigen Therapeutic Vaccine - marketscreener.com

Transgene has announced the expansion of its myvac® platform into NSCLC via TG4070, an individualized neoantigen therapeutic vaccine. The company is leveraging its proprietary technology to target personalized antigens in this major solid tumor indication, marking a strategic broadening of its commercial pipeline beyond previous indications.

Transgene
news · brief 2026-06-22 · published 2026-06-22
05
Commercial

Transgene Expands myvac® into Non-Small Cell Lung Cancer with TG4070, an Individualized Neoantigen Therapeutic Vaccine - The Manila Times

Reports confirm Transgene's entry of TG4070 into the NSCLC market as part of its myvac® portfolio. By targeting individualized neoantigens, Transgene aims to capitalize on the growing commercial interest in personalized cancer vaccines, positioning TG4070 as a key asset in its expanding therapeutic lineup.

Transgene
news · brief 2026-06-22 · published 2026-06-22
06
Commercial

Transgene Expands myvac® into Non-Small Cell Lung Cancer with TG4070, an Individualized Neoantigen Therapeutic - Boursorama

Transgene is advancing TG4070, an individualized neoantigen vaccine under its myvac® platform, into non-small cell lung cancer. This development highlights the company's strategy to apply its personalized vaccine technology across multiple solid tumor types, though no specific trial phases or efficacy outcomes were disclosed in the current reports.

Transgene
news · brief 2026-06-22 · published 2026-06-22
08
Clinical

Clinical Study of the Therapeutic Effectiveness of In-silico-Designed, Machine Learning Inspired, and Quantum-molecularly Coupled Personalized Neoantigenic Vaccines Microlyvaq™ in Patients With Advanced Non-small Cell Lung Cancer

Biogenea is conducting a two-arm trial of Microlyvaq™, an in-silico-designed personalized multi-epitope vaccine, in advanced non-small cell lung cancer. The vaccine is added to standard chemo-immunotherapy (carboplatin/pembrolizumab plus histology-specific chemotherapy) to address resistance mechanisms like T-cell exhaustion and antigen loss.

clinicaltrials · brief 2026-06-13 · published 2025-12-16
10
Clinical

Safety and Efficacy of Neoantigen-Based Personalized Immunotherapy as Consolidation Therapy After Standard Adjuvant Treatment in Resectable Stage III Colorectal Cancer or Non-Small Cell Lung Cancer

Ying Yuan has completed a phase 1 study evaluating neoantigen-based personalized immunotherapy as consolidation therapy after standard adjuvant treatment in resectable stage III colorectal cancer and NSCLC. The trial confirmed that the 300 μg/peptide dose is well-tolerated, establishing safety for future efficacy assessments.

Peptide vaccinesColorectal cancer
clinicaltrials · brief 2026-06-08 · published 2026-03-31
11
Clinical

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

Fred Hutchinson Cancer Center is recruiting for a phase 1 trial of a personalized neo-antigen peptide vaccine combined with the Th1 polarizing adjuvant poly ICLC. The study targets stage IIIC-IV melanoma, metastatic breast cancer, and stage III-IV NSCLC to induce polyclonal cytolytic T cell immunity.

Peptide vaccinesMelanomaBreast cancer
clinicaltrials · brief 2026-06-08 · published 2026-03-12
13
Clinical

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

Fred Hutchinson Cancer Center has launched a Phase I trial recruiting patients with stage IIIC-IV melanoma, metastatic breast cancer, or stage III-IV NSCLC. The study evaluates a personalized neo-antigen peptide vaccine combined with the Th1-polarizing adjuvant poly ICLC to induce polyclonal cytolytic T cell immunity.

Peptide vaccinesMelanomaBreast cancer
clinicaltrials · brief 2026-06-02 · published 2026-03-12
15
Clinical

Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab

UNC Lineberger Comprehensive Cancer Center has suspended a Phase I trial of the PANDA-VAC personalized neoantigen peptide vaccine administered concurrently with pembrolizumab. The study was designed for advanced squamous NSCLC and head and neck squamous cell carcinoma, assessing safety and dose adjustment protocols.

Peptide vaccinesHead & neck cancer
clinicaltrials · brief 2026-06-02 · published 2026-04-23
Where nextAll topicsToday’s briefTrials tracker